{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:22:31Z","timestamp":1794576151298,"version":"4.9.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.curtheres.2026.100833","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:58:25Z","timestamp":1779951505000},"page":"100833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety"],"prefix":"10.1016","volume":"105","author":[{"given":"Niloofar","family":"Masoumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Monadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Aminzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesam","family":"Noqani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ehsan","family":"Enderami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2026.100833_bib0001","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/jcm9061632","article-title":"Prevalence and comorbidity of atopic dermatitis in children: a large-scale population study based on real-world data","volume":"9","author":"Gilaberte","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0002","first-page":"161","article-title":"Atopic dermatitis in children: clinical features, pathophysiology, and treatment","volume":"35","author":"Lyons","year":"2015","journal-title":"Immunol Allergy Clin"},{"key":"10.1016\/j.curtheres.2026.100833_bib0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2340\/00015555-3513","article-title":"Genetics in atopic dermatitis: historical perspective and future prospects","volume":"100","author":"Brown","year":"2020","journal-title":"Acta dermato-Venereologica"},{"key":"10.1016\/j.curtheres.2026.100833_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdermsci.2018.03.005","article-title":"An overview of epidermal lamellar bodies: novel roles in biological adaptations and secondary barriers","volume":"92","author":"Menon","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.curtheres.2026.100833_bib0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/jcm4040593","article-title":"Biological treatments in atopic dermatitis","volume":"4","author":"Montes-Torres","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0006","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"0","key":"10.1016\/j.curtheres.2026.100833_bib0007","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2147\/CCID.S517415","article-title":"Malassezia Globosa aggravates atopic dermatitis by influencing the Th1\/Th2 related cytokines in mouse models","volume":"18","author":"Wu","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40259-017-0241-6","article-title":"Monoclonal antibodies for atopic dermatitis: progress and potential","volume":"31","author":"Vakharia","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.curtheres.2026.100833_bib0009","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s13346-017-0439-7","article-title":"Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects","volume":"9","author":"Siddique","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.curtheres.2026.100833_bib0011","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12016-020-08802-9","article-title":"Current and future monoclonal antibodies in the treatment of atopic dermatitis","volume":"59","author":"Chun","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14712598.2024.2368192","article-title":"Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond","volume":"24","author":"David","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.02.001","article-title":"New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity","volume":"70","author":"Kabashima","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.curtheres.2026.100833_bib0014","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2017.04.010","article-title":"Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases","volume":"139","author":"Schleimer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaci.2008.08.002","article-title":"Filaggrin in atopic dermatitis","volume":"122","author":"O'Regan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0016","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0017","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","article-title":"Atopic dermatitis and the atopic march","volume":"112","author":"Spergel","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0018","first-page":"359","article-title":"Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis?","volume":"96","author":"Silverberg","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.curtheres.2026.100833_bib0019","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2215\/CJN.04680514","article-title":"How the innate immune system senses trouble and causes trouble","volume":"10","author":"Hato","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0020","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3390\/biomedicines9121795","article-title":"Soluble factors and receptors involved in skin innate immunity\u2014what do we know so far?","volume":"9","author":"Scurtu","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.curtheres.2026.100833_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7774\/cevr.2014.3.1.12","article-title":"New vaccines against influenza virus","volume":"3","author":"Lee","year":"2014","journal-title":"Clin Experiment Vaccine Res"},{"key":"10.1016\/j.curtheres.2026.100833_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2014.12.012","article-title":"Viral RNA detection by RIG-I-like receptors","volume":"32","author":"Yoneyama","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-065X.2008.00734.x","article-title":"Function of Nod-like receptors in microbial recognition and host defense","volume":"227","author":"Franchi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.curtheres.2026.100833_bib0024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.intimp.2013.04.013","article-title":"The role of C-type lectin receptors in immune homeostasis","volume":"16","author":"Yan","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.curtheres.2026.100833_bib0026","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clindermatol.2017.03.006","article-title":"Current and emerging concepts in atopic dermatitis pathogenesis","volume":"35","author":"Sullivan","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0027","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3390\/microorganisms13081950","article-title":"BCL-2 multi-strain probiotics for immunomodulation In vitro and In vivo alleviation of atopic dermatitis","volume":"13","author":"Sung","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.curtheres.2026.100833_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696784","article-title":"Th2 Modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis","volume":"12","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0029","first-page":"925","article-title":"IL-4 and IL-13 inhibition in atopic dermatitis","volume":"15","author":"Matsunaga","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.curtheres.2026.100833_bib0032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11882-020-00937-1","article-title":"The role of new IL-1 Family members (IL-36 and IL-38) in atopic dermatitis, allergic asthma, and allergic rhinitis","volume":"20","author":"Tsang","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0033","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: Clinical implications","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.curtheres.2026.100833_bib0034","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0035","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jaci.2017.12.1002","article-title":"New mechanism underlying IL-31\u2013induced atopic dermatitis","volume":"141","author":"Meng","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107648","article-title":"TSLP as druggable target - a silver-lining for atopic diseases?","volume":"217","author":"Adhikary","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0037","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/14789450.2013.814881","article-title":"Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis","volume":"10","author":"Indra","year":"2013","journal-title":"Expert Rev Proteom"},{"key":"10.1016\/j.curtheres.2026.100833_bib0038","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.curtheres.2026.100833_bib0039","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell\u2013mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0040","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1084\/jem.20061675","article-title":"Interleukin 25 promotes the initiation of proallergic type 2 responses","volume":"204","author":"Angkasekwinai","year":"2007","journal-title":"J Experiment Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0041","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proceed Natl Acad Sci"},{"key":"10.1016\/j.curtheres.2026.100833_bib0042","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1604","article-title":"Type 2 immunity: expanding our view","volume":"3","author":"Lloyd","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0043","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imr.12558","article-title":"IL-25 in allergic inflammation","volume":"278","author":"Xu","year":"2017","journal-title":"Immunolog Rev"},{"key":"10.1016\/j.curtheres.2026.100833_bib0044","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.3390\/ijms19103086","article-title":"New cytokines in the pathogenesis of atopic dermatitis\u2014new therapeutic targets","volume":"19","author":"Klonowska","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.curtheres.2026.100833_bib0045","article-title":"The role of ILC2s in asthma combined with atopic dermatitis: bridging the gap from research to clinical practice","volume":"16","author":"Luo","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0046","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1172\/JCI1647","article-title":"Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice","volume":"101","author":"Spergel","year":"1998","journal-title":"J Clin Investig"},{"key":"10.1016\/j.curtheres.2026.100833_bib0047","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.3892\/mmr.2017.7689","article-title":"P38\/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL\u201117","volume":"16","author":"Tan","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0048","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for treatment of atopic dermatitis: current status and future prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.curtheres.2026.100833_bib0049","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14712598.2020.1722998","article-title":"Efficacy of biologics in atopic dermatitis","volume":"20","author":"Wu","year":"2020","journal-title":"Expert Opin Biologic Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0050","first-page":"532","article-title":"Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D\u2019Ippolito","year":"2018","journal-title":"Pharm Therap"},{"key":"10.1016\/j.curtheres.2026.100833_bib0051","first-page":"532","article-title":"Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D\u2019Ippolito","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.curtheres.2026.100833_bib0052","article-title":"Dupilumab in dermatology: potential for uses beyond atopic dermatitis","volume":"18","author":"Maloney","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0053","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rbmo.2021.10.006","article-title":"An artificial intelligence platform to optimize workflow during ovarian stimulation and IVF: process improvement and outcome-based predictions","volume":"44","author":"Letterie","year":"2022","journal-title":"Reprod BioMed Online"},{"key":"10.1016\/j.curtheres.2026.100833_bib0054","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2026.100833_bib0055","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab treatment in children aged 6\u201311 years with atopic dermatitis: a multicentre, real-life study","volume":"24","author":"Napolitano","year":"2022","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.curtheres.2026.100833_bib0056","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/pde.14909","article-title":"Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis\u2014a pooled analysis of trial data","volume":"39","author":"Paller","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0057","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/pde.13707","article-title":"Use of dupilimab in pediatric atopic dermatitis: access, dosing, and implications for managing severe atopic dermatitis","volume":"36","author":"Siegfried","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0058","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0059","doi-asserted-by":"crossref","first-page":"705","DOI":"10.15171\/apb.2018.079","article-title":"Physiological and biochemical effects of echium amoenum extract on Mn(2+)-imposed parkinson like disorder in rats","volume":"8","author":"Sadeghi","year":"2018","journal-title":"Adv Pharmaceut Bulletin"},{"key":"10.1016\/j.curtheres.2026.100833_bib0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/cpt.2366","article-title":"The posology of dupilumab in pediatric patients with atopic dermatitis","volume":"110","author":"Kamal","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0061","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab treatment in children aged 6\u201311 years with atopic dermatitis: a multicentre, real-life study","volume":"24","author":"Napolitano","year":"2022","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.curtheres.2026.100833_bib0062","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0063","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2026.100833_bib0064","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study","volume":"184","author":"Cork","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0066","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0067","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.18476","article-title":"Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension","volume":"182","author":"Cork","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0068","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/pde.13697","article-title":"Long-term off-label dupilumab in pediatric atopic dermatitis: a case series","volume":"36","author":"Treister","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0069","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of Dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0070","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3368","article-title":"Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: a case series","volume":"100","author":"Mareschal","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0071","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13887","article-title":"Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry","volume":"33","author":"Kamphuis","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0072","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/pde.14909","article-title":"Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis\u2014a pooled analysis of trial data","volume":"39","author":"Paller","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0073","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jdcr.2019.03.019","article-title":"Alopecia areata in 2 patients treated with dupilumab: new onset and worsening","volume":"5","author":"Chung","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0074","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","article-title":"Drug-induced alopecia after dupilumab therapy","volume":"5","author":"Flanagan","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0076","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2021.07.015","article-title":"Dupilumab for the treatment of alopecia areata in children with atopic dermatitis","volume":"16","author":"Cho","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0077","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2021.01.046","article-title":"Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis","volume":"84","author":"McKenzie","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0078","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/pde.14799","article-title":"Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: inadequate response and adverse events","volume":"38","author":"McKenzie","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0079","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.3389\/fmicb.2018.02618","article-title":"Purification and characterization of an active principle, Lawsone, responsible for the plasmid curing activity of plumbago zeylanica root extracts","volume":"9","author":"Patwardhan","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/pde.14499","article-title":"New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis","volume":"38","author":"Bax","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0081","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-021-00607-6","article-title":"Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020","volume":"22","author":"Martinez-Cabriales","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0082","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/ACI.0000000000000455","article-title":"Monoclonal antibodies for the treatment of atopic dermatitis","volume":"18","author":"Renert-Yuval","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0083","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s40265-021-01583-1","article-title":"Tralokinumab: first approval","volume":"81","author":"Duggan","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.curtheres.2026.100833_bib0084","author":"Hewett"},{"key":"10.1016\/j.curtheres.2026.100833_bib0085","unstructured":"European Medicines Agency. Adtralza (tralokinumab): EPAR - Medicine overview. Amsterdam: EMA; 2021 [cited 2025 Jun 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adtralza"},{"key":"10.1016\/j.curtheres.2026.100833_bib0086","first-page":"1","article-title":"Tralokinumab (Adtralza)","volume":"2","year":"2022","journal-title":"Can J Health Technol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0087","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0088","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Brit J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0089","first-page":"E90","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial","volume":"187","author":"Paller","year":"2022","journal-title":"Brit J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0090","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/bjd\/ljad007","article-title":"Safety of tralokinumab in atopic dermatitis","volume":"188","author":"Simpson","year":"2023","journal-title":"Brit J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0091","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/JAA.S211032","article-title":"Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis","volume":"13","author":"Loh","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.curtheres.2026.100833_bib0092","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0093","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/jid.2014.362","article-title":"Omalizumab, an anti-IgE mAb, receives approval for the treatment of chronic idiopathic\/spontaneous urticaria","volume":"135","author":"Wu","year":"2015","journal-title":"J Investigat Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-017-1976-6","article-title":"The role of anti-IgE (omalizumab\/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan","volume":"18","author":"Chen","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.curtheres.2026.100833_bib0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.curtheres.2026.100833_bib0096","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0097","article-title":"Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective","volume":"33","author":"Iannelli","year":"2020","journal-title":"Dermatolog Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0098","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2013.05.035","article-title":"Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective","volume":"69","author":"Lacombe Barrios","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0099","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamapediatrics.2019.4509","article-title":"Omalizumab for atopic dermatitis: overtreatment or Lifesaver?","volume":"174","author":"Wu","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.curtheres.2026.100833_bib0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis: a systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.curtheres.2026.100833_bib0101","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0103","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","article-title":"Pharmacokinetics, safety, efficacy, and biomarker profiles during Nemolizumab treatment of atopic dermatitis in adolescents","volume":"12","author":"Sidbury","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0106","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of Lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0107","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17512433.2023.2173172","article-title":"Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis","volume":"16","author":"Moreno","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0109","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Brit J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s13555-022-00868-x","article-title":"Modern Interventions for pediatric atopic dermatitis: an updated pharmacologic approach","volume":"13","author":"Kondratuk","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.curtheres.2026.100833_bib0111","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13256-021-02663-2","article-title":"Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report","volume":"15","author":"Pham","year":"2021","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.curtheres.2026.100833_bib0112","first-page":"e1211","article-title":"Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial","volume":"37","author":"Guttman-Yassky","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0113","article-title":"The new era of biologics in atopic dermatitis: a review","volume":"11","author":"Schneider","year":"2021","journal-title":"Dermatol Practic Conceptual"},{"key":"10.1016\/j.curtheres.2026.100833_bib0114","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.curtheres.2026.100833_bib0115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0116","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0117","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis: a systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J Dermatol Treatm"},{"key":"10.1016\/j.curtheres.2026.100833_bib0118","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.curtheres.2026.100833_bib0119","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.jid.2023.01.040","article-title":"IgE depletion with Ligelizumab does not significantly improve clinical symptoms in patients with moderate-to-severe atopic dermatitis","volume":"143","author":"Bangert","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.curtheres.2026.100833_bib0121","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22\u2013producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17\u2013producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0122","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdermsci.2010.08.013","article-title":"Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis","volume":"61","author":"Hayashida","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.curtheres.2026.100833_bib0123","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0124","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0125","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0127","first-page":"190","article-title":"Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis","volume":"23","author":"Sanchez-Ramon","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1684\/ejd.2018.3476","article-title":"Rituximab revisited: successful management of severe childhood atopic dermatitis","volume":"29","author":"Duarte","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.curtheres.2026.100833_bib0129","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2026.1766021","article-title":"Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipeline","volume":"6","author":"Amid-Toby","year":"2026","journal-title":"Front Drug Discov"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:23:56Z","timestamp":1794572636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X26000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":129,"alternative-id":["S0011393X26000147"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100833","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100833"}}